Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POETYK PSO-LTE: Long-Term Extension Study of Deucravacitinib in Plaque Psoriasis
NCT04036435Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2019
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Started Aug 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04036435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04036435.